UMB inks second licensing deal with spinout developing cancer treatments - Technical.ly Baltimore

Sciences

Dec. 19, 2018 11:06 am

UMB inks second licensing deal with spinout developing cancer treatments

Educational & Scientific will look to take a molecule that inhibits the growth of prostate cancer to market.
Taking a closer look at Maryland’s life sciences and medtech startups.

Taking a closer look at Maryland's life sciences and medtech startups.

(Photo via Shutterstock.com)

A startup developing new cancer treatments recently signed its second tech transfer deal with the University of Maryland, Baltimore.

Three-year-old Educational & Scientific, LLC (ESL) licensed technology designed to inhibit growth of prostate cancer with a specific form of the disease, according to UM Ventures. The molecule was developed as a therapeutic agent by University of Maryland School of Medicine professors Vincent C.O. Njar and Angela Brodie. 

E. Albert Reece, dean of the University of Maryland School of Medicine Dean, said the collaboration is “a great example of how we can combine basic science with new potential therapies to treat cancer.”

“We are pleased to broaden our oncology portfolio with this exciting molecule and are even more pleased to be advancing a treatment that could help prostate cancer patients who presently have limited therapeutic options,” ESL Founder Henry Lowe said in a statement.

Baltimore-based ESL is working to examine medicinal plants in Jamaica for potential therapeutic purposes. It’s an area in which Lowe has made significant contributions that resulted in new businesses. The startup signed an initial licensing agreement with the university to develop a cancer treatment derived from the Jamaican plant Ball Moss that was co-invented by Lowe, company CEO Ngeh J. Toyang and former School of Medicine Professor Joseph Bryant.

The recent deal for the molecule provides a second, yet separate, technology that the company will develop simultaneously, and one that is moving toward an advanced stage of development. Known as Galeterone, the molecule was already successful in Phase 1 and Phase 2 trials in patients, and the team is planning Phase 3 trials later in 2019. The third phase often involve numerous patients across multiple sites, and is the final phase before regulatory approval.

Given Lowe’s experience and the stage of development, adding the second technology “helps them from a strategic perspective a lot,” said UMB Chief Commercialization Officer Phil Robilotto.

Advertisement

-30-
BECOME A CONTRIBUTOR TO THE JOURNALISM FUND TO COMMENT
Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

University of Maryland awarded $200M for flu vaccine research

Early Charm Ventures launches Abri Science with $225K in funding

Intelehealth launches crowdfunding campaign to expand primary care access around the world

SPONSORED

Baltimore

Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program

Baltimore

Protenus

DevOps Engineer

Apply Now

Philadelphia

Vistar Media

Sr. Software Engineer

Apply Now

Philadelphia

Vistar Media

Front End Engineer

Apply Now

Between Two Founders: The moments that led to VitusVet’s pet health app

MICA Game Lab and Shock Trauma are developing VR games for spinal injury patients

Loyola is launching an online learning platform with courses in cybersecurity, data science

SPONSORED

Baltimore

What Asymmetrik is doing to help lead healthcare’s digital transformation

Baltimore, MD

14 West

BI TechOps Analyst

Apply Now

Baltimore, MD

14 West

Scrum Master

Apply Now

Baltimore, MD

14 West

Lead Qlik Developer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!